Literature DB >> 30410662

Tyrosine Kinase Inhibitor-Induced Acute Myocarditis, Myositis, and Cardiogenic Shock.

Majid Asawaeer1, David Barton1, Stanley Radio1, Yiannis S Chatzizisis1.   

Abstract

Entities:  

Keywords:  acute myocarditis; adverse events; sorafenib; tyrosine kinase inhibitors

Mesh：

Substances：

Year:  2018        PMID： 30410662      PMCID： PMC6217568          DOI： 10.14797/mdcj-14-3-e5

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN： 1947-6108


× No keyword cloud information.
  3 in total

Review 1.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

2.  Sorafenib cardiotoxicity increases mortality after myocardial infarction.

Authors:  Jason M Duran; Catherine A Makarewich; Danielle Trappanese; Polina Gross; Sharmeen Husain; Jonathan Dunn; Hind Lal; Thomas E Sharp; Timothy Starosta; Ronald J Vagnozzi; Remus M Berretta; Mary Barbe; Daohai Yu; Erhe Gao; Hajime Kubo; Thomas Force; Steven R Houser
Journal:  Circ Res       Date:  2014-04-09       Impact factor: 17.367

3.  Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.

Authors:  Manuela Schmidinger; Christoph C Zielinski; Ursula M Vogl; Andja Bojic; Marija Bojic; Christoph Schukro; Marquerite Ruhsam; Michael Hejna; Herwig Schmidinger
Journal:  J Clin Oncol       Date:  2008-10-06       Impact factor: 44.544
  3 in total
  2 in total

1.  Myopericarditis and myositis in a patient with COVID-19: a case report.

Authors:  Asad Shabbir; Christian Fielder Camm; Andrew Elkington; Lindsey Tilling; James Stirrup; Antoni Chan; Sacha Bull
Journal:  Eur Heart J Case Rep       Date:  2020-10-30

Review 2.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.

Authors:  Joerg Herrmann
Journal:  Nat Rev Cardiol       Date:  2020-03-30       Impact factor: 32.419
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.